In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

CytomX pens Probody deal with Bristol

Executive Summary

CytomX Therapeutics Inc. (next-generation, targeted antibodies) licensed Bristol-Myers Squibb Co. exclusive worldwide rights to discover, develop, and sell Probodies interacting with up to four immuno-oncology targets, including cytotoxic T-lymphocyte antigen-4 (CTLA-4).

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
    • Immuno-Oncology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies